Dikla Axselbrad on biotech funding
From Ep607: Dikla Czaczkes Akselbrad | Executive Vice President and Chief Financial Officer, PolyPid · · The Matias Experiment
“In the biotech industry the one thing that is missing more than anything else is funding, because this is a long journey that will take years and you need to find it along these years and create a financial strategy that will support the company while it's private and then public.”
On , Dikla Axselbrad, CEO at PolyPid, spoke about biotech funding during Ep607: Dikla Czaczkes Akselbrad | Executive Vice President and Chief Financial Officer, PolyPid on The Matias Experiment.
About Dikla Axselbrad
Dikla Axselbrad, CEO of PolyPid, stated in January 2026 that the company is transitioning from a development-stage to a commercial-stage company. She said PolyPid plans to submit a New Drug Application (NDA) early in 2026, with a rolling submission eligible under Breakthrough Therapy designation, and expects a PDUFA action date around early 2027. Axselbrad also noted that the company intends to announce a US deal in the coming months and advance its pipeline, including a GLP-1 product. In a 2022 interview, Axselbrad described her role as CFO as that of a "Chief Focus Officer" in an innovation company, emphasizing the need for consistency in long-term strategy and creativity in day-to-day operations. She stated that funding is the most critical missing element in the biotech industry due to the lengthy development journey.